This website is for US healthcare professionals


Log In to Bolder Science


Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

  • identifier


  • Recruitment Status


  • First Posted

    May 1, 2019

  • Last update posted

    December 19, 2020

Study Description

Brief summary:

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study consists of 2 portions, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B). Arm A will evaluate the safety, tolerability, PK and PD profiles of escalating doses of single-agent TNB-383B, administered once every 3 weeks (Q3W), in approximately 85 subjects. Once the maximum tolerated dose (MTD) or recommended phase 2 dose, (RP2D) is identified in Arm A, Arm B will be initiated to further characterize the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the MTD/RP2D dose of TNB 383B monotherapy in approximately 48 subjects.

  • Condition or Disease:Multiple Myeloma
  • Intervention/Treatment: Drug: TNB-383B
  • Phase: Phase 1

Detailed Description


Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 133 participants
  • Allocation: Non-Randomized
  • Intervention Model: Sequential Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
  • Actual Study Start Date: June 2019
  • Estimated Primary Completion Date: December 2021
  • Estimated Study Completion Date: December 2021

Arms and interventions

Arm Intervention/treatment
Experimental: Arm A: Dose Escalation
Up to 15 cohorts of subjects receiving sequentially ascending doses of TNB-383B are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified.
Drug: TNB-383B
TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
Experimental: Arm B: Dose Expansion
An expansion cohort will be enrolled after maximum tolerated dose or recommended phase 2 dose is established.
Drug: TNB-383B
TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.

Outcome Measures

  • Primary Outcome Measures: 1. Number of subjects with Dose-limiting toxicities (DLT) [ Time Frame: 21 days ]
  • 2. Number of subjects with adverse events (AEs) and/or serious adverse events (SAEs) [ Time Frame: From screening until 90 Days after end of treatment ]
    The incidence, timing, seriousness, and relationship to study treatments of adverse events will be evaluated. An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.
  • 3. Maximum Observed Plasma Concentration of TNB-383B (Cmax) [ Time Frame: 12 weeks ]
    Cmax of TNB-383B will be calculated
  • 4. Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast) [ Time Frame: 12 weeks ]
    AUClast of TNB-383B will be calculated.
  • 5. Apparent terminal half-life (t1/2) of TNB-383B. [ Time Frame: 12 weeks ]
    t1/2 of TNB-383B will be calculated
  • Secondary Outcome Measures: 1. Incidence of Anti-drug Antibody (ADA) [ Time Frame: 48 months ]
    The number of participants with anti-TNB-383B antibodies
  • 2. Titers of Anti-drug Antibody (ADA) [ Time Frame: 48 months ]
    The titers of anti-TNB-383B antibodies
  • 3. Anti-Myeloma Activity by Objective Response Rate (ORR) [ Time Frame: 48 months ]
    The objective response rate, defined as the proportion of subjects with a confirmed partial (PR) or complete (CR) response to treatment as determined using International Myeloma Working Group (IMWG) uniform response criteria
  • 4. Anti-Myeloma Activity by Duration of Objective Response (DOR) [ Time Frame: 48 months ]
    Duration of objective response is measured as the time from the initial objective response to disease progression or death, whichever occurs first.

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No


Inclusion Criteria:

- Subjects with Relapsed/Refractory Multiple Myeloma.

- Subject has received three or more prior lines of therapy with exposure to a
proteasome inhibitor (PI), an immunomodulatory imide (IMiD) and an anti-CD38
monoclonal antibody (e.g., daratumumab).

- Subject has Measurable Disease, defined as at least 1 of the following:

- Serum M-protein ≥ 0.5 g/dL (≥ 5 g/L)

- Urine M-protein ≥ 200 mg / 24h

- Serum free light chain (FLC) assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/L)
and an abnormal serum FLC ratio ( 1.65).

- Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.

- Prior bone marrow transplant is acceptable if subject is > 12 weeks (autologous) or >
1 year (allogeneic) status-post transplantation

- Subject must have adequate bone marrow function, defined as:

- absolute neutrophil count (ANC) ≥ 1000/mm3;

- platelets ≥ 50,000/mm3;

- hemoglobin ≥ 8.0 g/dL.

- Subject must have an eGFR ≥ 30 mL/min as estimated by the MDRD formula.

- Subject must have total bilirubin ≤ 1.5 × upper limit of normal (ULN; except if the
subject has a known diagnosis of Gilbert's syndrome, in which case bilirubin must be < 3 x ULN). - Serum calcium (corrected for albumin) at or below the ULN range. Exclusion Criteria: - Subject has ever received BCMA-targeted therapy. Subjects who have received targeted therapy against non-BCMA targets will not be excluded - Subject has a history of central nervous system involvement by their myeloma. - Subject has a history of ≥ Grade 3 peripheral neuropathy. - Subject has a history of plasma cell leukemia, POEMS syndrome, or amyloidosis. - Subject has received any therapy to treat cancer or undergone a major surgical procedure within 21 days, or within 5 half-lives of an anticancer drug, prior to the first dose of study treatment, whichever is shorter. - Subject has a history of major cardiac abnormalities. - Subject has a known active infection requiring parenteral anti-infective treatment

Contacts and Locations


Contact: Ben Buelow, MD, PhD (650) 899-8222


United States, California
San Francisco

United States, Minnesota
Mayo Clinic-Rochester

United States, Missouri
Washington University
Saint Louis

United States, North Carolina
Carolinas Healthcare

United States, North Carolina
Wake Forest

United States, Wisconsin
Froedtert Hospital & the Medical College of Wisconsin

Sponsors and Collaborators

Teneobio, Inc.



Study Chair: Ben Buelow, MD, PhD Teneobio, Inc.

More Information

  • Responsible Party: Teneobio, Inc.
  • Identifier: NCT03933735 History of Changes
  • Other Study ID Numbers: TNB383B.0001
  • First Posted: May 1, 2019 Key Record Dates
  • Last Update Posted: December 19, 2020
  • Last Verified: December 2020
  • Individual Participant
    Data (IPD) Sharing

  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Neoplasms, Plasma Cell Multiple Myeloma